Catheter Precision (VTAK) announces that it has closed the previously announced acquisition of PeriKard. David Jenkins, CEO of Catheter Precision, commented on the acquisition, “We are happy to have closed on this all-stock transaction within our anticipated timeline. The acquired technology will complement our emphasis on the ventricular therapeutic market and expectation for continuing growth in this market segment”.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTAK: